54 related articles for article (PubMed ID: 17921847)
1. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
Stastny MJ; Brown CE; Ruel C; Jensen MC
J Pediatr Hematol Oncol; 2007 Oct; 29(10):669-77. PubMed ID: 17921847
[TBL] [Abstract][Full Text] [Related]
2. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P
Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020
[TBL] [Abstract][Full Text] [Related]
3. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
Gu A; Bai Y; Zhang C; Xu C; An Z; Zhang Y; Zhong SH; Hu Y; Zhong X
Cancer Immunol Immunother; 2023 Jul; 72(7):2393-2403. PubMed ID: 36991262
[TBL] [Abstract][Full Text] [Related]
4. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
Stern LA; Gholamin S; Moraga I; Yang X; Saravanakumar S; Cohen JR; Starr R; Aguilar B; Salvary V; Hibbard JC; Kalbasi A; Shepphird JK; O'Hearn J; Garcia KC; Brown CE
Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2112006119. PubMed ID: 35939683
[TBL] [Abstract][Full Text] [Related]
5. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.
Nellan A; Rota C; Majzner R; Lester-McCully CM; Griesinger AM; Mulcahy Levy JM; Foreman NK; Warren KE; Lee DW
J Immunother Cancer; 2018 Apr; 6(1):30. PubMed ID: 29712574
[TBL] [Abstract][Full Text] [Related]
6. Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy.
Flores C; Wildes T; Dean BD; Moore G; Drake J; Abraham R; Gil J; Yegorov O; Yang C; Dean J; Moneypenny C; Shin D; Pham C; Krauser J; King J; Grant G; Driscoll T; Kurtzberg J; McLendon R; Gururangan S; Mitchell D
Sci Adv; 2019 Nov; 5(11):eaav9879. PubMed ID: 31807694
[TBL] [Abstract][Full Text] [Related]
7. High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma.
Kim GB; Aragon-Sanabria V; Randolph L; Jiang H; Reynolds JA; Webb BS; Madhankumar A; Lian X; Connor JR; Yang J; Dong C
Bioact Mater; 2020 Sep; 5(3):624-635. PubMed ID: 32405577
[TBL] [Abstract][Full Text] [Related]
8. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
[TBL] [Abstract][Full Text] [Related]
9.
Bhojnagarwala PS; O'Connell RP; Park D; Liaw K; Ali AR; Bordoloi D; Cassel J; Tursi NJ; Gary E; Weiner DB
Mol Ther Oncolytics; 2022 Sep; 26():289-301. PubMed ID: 36090479
[TBL] [Abstract][Full Text] [Related]
10. CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia.
Wang X; Dong Z; Awuah D; Chang WC; Cheng WA; Vyas V; Cha SC; Anderson AJ; Zhang T; Wang Z; Szymura SJ; Kuang BZ; Clark MC; Aldoss I; Forman SJ; Kwak LW; Qin H
Leukemia; 2022 Apr; 36(4):1015-1024. PubMed ID: 35039637
[TBL] [Abstract][Full Text] [Related]
11. The Growing Relevance of Immunoregulation in Pediatric Brain Tumors.
Melcher V; Kerl K
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830753
[TBL] [Abstract][Full Text] [Related]
12. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
[TBL] [Abstract][Full Text] [Related]
13. Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma.
Shackleford GM; Mahdi MY; Moats RA; Hawes D; Tran HC; Finlay JL; Hoang TQ; Meng EF; Erdreich-Epstein A
PLoS One; 2019; 14(1):e0206394. PubMed ID: 30608927
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression in medulloblastoma: an evaluation by subgroup.
Martin AM; Nirschl CJ; Polanczyk MJ; Bell WR; Nirschl TR; Harris-Bookman S; Phallen J; Hicks J; Martinez D; Ogurtsova A; Xu H; Sullivan LM; Meeker AK; Raabe EH; Cohen KJ; Eberhart CG; Burger PC; Santi M; Taube JM; Pardoll DM; Drake CG; Lim M
Oncotarget; 2018 Apr; 9(27):19177-19191. PubMed ID: 29721192
[TBL] [Abstract][Full Text] [Related]
15. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
16. Comparison of naïve and central memory derived CD8
Wang X; Wong CW; Urak R; Taus E; Aguilar B; Chang WC; Mardiros A; Budde LE; Brown CE; Berger C; Forman SJ; Jensen MC
Oncoimmunology; 2016; 5(1):e1072671. PubMed ID: 26942092
[TBL] [Abstract][Full Text] [Related]
17. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.
Wang X; Wong CW; Urak R; Mardiros A; Budde LE; Chang WC; Thomas SH; Brown CE; La Rosa C; Diamond DJ; Jensen MC; Nakamura R; Zaia JA; Forman SJ
Clin Cancer Res; 2015 Jul; 21(13):2993-3002. PubMed ID: 25838392
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy.
Jonnalagadda M; Mardiros A; Urak R; Wang X; Hoffman LJ; Bernanke A; Chang WC; Bretzlaff W; Starr R; Priceman S; Ostberg JR; Forman SJ; Brown CE
Mol Ther; 2015 Apr; 23(4):757-68. PubMed ID: 25366031
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas.
Teo WY; Elghetany MT; Shen J; Man TK; Li X; Chintagumpala M; Su JM; Dauser R; Whitehead W; Adesina AM; Lau CC
J Neurooncol; 2014 Nov; 120(2):293-301. PubMed ID: 25115738
[TBL] [Abstract][Full Text] [Related]
20. Engineered T cells for cancer treatment.
Anurathapan U; Leen AM; Brenner MK; Vera JF
Cytotherapy; 2014 Jun; 16(6):713-33. PubMed ID: 24239105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
